Back to Search
Start Over
Defining the Role of Novel β-Lactam Agents That Target Carbapenem-Resistant Gram-Negative Organisms
- Source :
- Journal of the Pediatric Infectious Diseases Society. 8:251-260
- Publication Year :
- 2019
- Publisher :
- Oxford University Press (OUP), 2019.
-
Abstract
- With the current carbapenem-resistant organism crisis, conventional approaches to optimizing pharmacokinetic-pharmacodynamic parameters are frequently inadequate, and traditional salvage agents (eg, colistin, tigecycline, etc) confer high toxicity and/or have low efficacy. However, several β-lactam agents with activity against carbapenem-resistant organisms were approved recently by the US Food and Drug Administration, and more are anticipated to be approved in the near future. The primary goal of this review is to assist infectious disease practitioners with preferentially selecting 1 agent over another when treating patients infected with a carbapenem-resistant organism. However, resistance to some of these antibiotics has already developed. Antibiotic stewardship programs can ensure that they are reserved for situations in which other options are lacking and are paramount for the survival of these agents.
- Subjects :
- 0301 basic medicine
Tazobactam
medicine.medical_specialty
medicine.drug_class
Avibactam
030106 microbiology
Antibiotics
Cilastatin, Imipenem Drug Combination
Tigecycline
Aztreonam
Ceftazidime
Heterocyclic Compounds, 1-Ring
03 medical and health sciences
chemistry.chemical_compound
0302 clinical medicine
Drug Resistance, Multiple, Bacterial
Gram-Negative Bacteria
polycyclic compounds
medicine
030212 general & internal medicine
Intensive care medicine
Organism
Invited Review
business.industry
Meropenem
General Medicine
biochemical phenomena, metabolism, and nutrition
Ceftazidime/avibactam
Boronic Acids
Anti-Bacterial Agents
Cephalosporins
Drug Combinations
Infectious Diseases
Carbapenems
chemistry
Infectious disease (medical specialty)
Pediatrics, Perinatology and Child Health
Colistin
Gram-Negative Bacterial Infections
business
Azabicyclo Compounds
medicine.drug
Subjects
Details
- ISSN :
- 20487207
- Volume :
- 8
- Database :
- OpenAIRE
- Journal :
- Journal of the Pediatric Infectious Diseases Society
- Accession number :
- edsair.doi.dedup.....3ac82ac82939782ae85d28eb451b0dfd